Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients

Twelve postmenopausal women suffering from advanced breast cancer had plasma estrogens, androgens, cortisol, and gonadotropins determined before therapy and during treatment with megestrol acetate (MA) in oral doses escalated from 40 to 160 mg. The plasma clearance and production rate of estrone and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 1996-09, Vol.2 (9), p.1515-1521
Main Authors: LUNDGREN, S, HELLE, S. I, LØNNING, P. E
Format: Article
Language:English
Subjects:
Administration, Oral
Aged
Androstenedione - blood
Antineoplastic agents
Appetite Stimulants - administration & dosage
Appetite Stimulants - therapeutic use
Area Under Curve
Biological and medical sciences
Breast Neoplasms - blood
Breast Neoplasms - drug therapy
Chemotherapy
Dehydroepiandrosterone Sulfate - blood
Dose-Response Relationship, Drug
Estrogens - blood
Estrone - analogs & derivatives
Estrone - blood
Estrone - pharmacokinetics
Female
Follicle Stimulating Hormone - blood
Humans
Hydrocortisone - blood
Luteinizing Hormone - blood
Medical sciences
Megestrol Acetate - administration & dosage
Megestrol Acetate - therapeutic use
Middle Aged
Pharmacology. Drug treatments
Postmenopause
Testosterone - blood
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twelve postmenopausal women suffering from advanced breast cancer had plasma estrogens, androgens, cortisol, and gonadotropins determined before therapy and during treatment with megestrol acetate (MA) in oral doses escalated from 40 to 160 mg. The plasma clearance and production rate of estrone and estrone sulfate were determined before treatment and after 4 weeks of therapy with 160 mg MA. Treatment with MA suppressed plasma levels of dehydroepiandrosterone sulfate, androstenedione, and cortisol in a dose-dependent manner to
ISSN:1078-0432
1557-3265